Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Sichuan Biokin Pharmaceutical (688506 CH)
Watchlist
22
Analysis
Health Care
•
China
Sichuan Biokin Pharmaceutical Co.,Ltd. operates as a pharmaceutical company. The Company produces children's medicine, cardiovascular drugs, anesthetics, chronic disease drugs, and more. Sichuan Biokin Pharmaceutical conducts businesses worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Sichuan Biokin Pharmaceutical
•
12 Jul 2024 12:38
•
Syndicated
Cutting-Edge Drugmaker Biokin Taps Hong Kong Market to Fund Foray Aboard
Chinese innovative drugmaker Sichuan Biokin Pharmaceutical Co. Ltd. has filed with the Hong Kong Stock Exchange for an initial public offering...
Caixin Global
Follow
251 Views
Share
bullish
•
Sichuan Biokin Pharmaceutical
•
26 Nov 2023 07:45
STAR50 Index Rebalance: Big Impact Expected; Inclusion Up 40% in One Month
There is 1 change for the index resulting in 1-way turnover of 2.18% and 1-way trade of CNY3.07bn. The add is up 40% over the last month and there...
Brian Freitas
Follow
530 Views
Share
bearish
•
Sichuan Biokin Pharmaceutical
•
24 Sep 2023 09:42
China Healthcare Weekly (Sep.22) - Medical Device VBP, Restore Optimism on Healthcare, Biokin Pharma
National VBP of intraocular lens/sports medicine medical consumables begins.Investors will maintain optimism when understand the logic behind...
Xinyao (Criss) Wang
Follow
543 Views
Share
bearish
•
HKEX
•
19 Nov 2023 05:30
Index Rebalance & ETF Flow Recap: FRTIB, Japan, CSI300, CSI500, STAR50, WuXi XDC, Asahi
This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...
Brian Freitas
Follow
615 Views
Share
bullish
•
Eoptolink Technology
•
15 Jul 2024 05:40
CSI300 Index Rebalance Preview: 18 Changes in Dec; Third Plenum; ETF Inflows; Short Sell Crackdown
There could be 18 changes in December. The adds have outperformed the deletes but near-term performance has been meh. There were ETF inflows last...
Brian Freitas
Follow
316 Views
Share
1
2
3
4
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.7
x